¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of SABCS : 2019-01-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of SABCS : 2019-01-19
±³À°ÀÏÀÚ : 2019-01-19
±³À°Àå¼Ò : È«Àºµ¿ ±×·£µåÈúÆ° ¿¡¸Þ¶öµåȦ  
±³À°ÁÖÁ¦ : Best of SABCS
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : ksmo1@ksmo.or.kr      
±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú      
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 35ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í »çÀüµî·Ï : Àü¹®ÀÇ 50000¿ø ÀüÀÓÀÇ 30000 ¿ø ±âŸ 70000¿ø ´çÀϵî·Ï : Àü¹®ÀÇ 60000¿ø ÀüÀÓÀÇ 40000 ¿ø ±âŸ 80000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 01-19 Emerald Hall 09:00~09:25 Insights in tumor heterogeneity and metastasis biology  ¾ÈÈñ°æ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 01-19 Emerald Hall 09:25~09:50 Translational insights in PI3K pathway and Immune system  TBD(TBD) 
Åä·Ð 01-19 Emerald Hall 09:50~09:55 Q & A  () 
±³À°½Ã°£ 01-19 Emerald Hall 09:55~10:20 Spotlight on prognostic/predictive biomarkers  Ã¤ÀǼö(°æºÏÀÇ´ë) 
±³À°½Ã°£ 01-19 Emerald Hall 10:20~10:45 Spotlight in current immunologic landscapes and therapeutics in breast cancer  ¿øÇý¼º(°¡Å縯ÀÇ´ë) 
Åä·Ð 01-19 Emerald Hall 10:45~10:50 Q & A  () 
È޽Ġ01-19  10:50~11:05 Coffee Break  () 
±³À°½Ã°£ 01-19 Emerald Hall 11:05~11:30 What  ÀÌÁ¤¾ð(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 01-19 Emerald Hall 11:30~11:55 Debates, Dilemma, and Consensus in radiation oncology  ±è±Ôº¸(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 01-19 Emerald Hall 11:55~12:20 Spotlights in supportive care and prevention including lifestyle intervention  ÀÌÁöÀº(°¡Å縯ÀÇ´ë) 
Åä·Ð 01-19 Emerald Hall 12:20~12:30 Q & A  () 
±³À°½Ã°£ 01-19 Emerald Hall 12:30~13:10 Advances in HR+/HER2- Breast Cancer: Clinical trial updates, Practice, Open Questions, and Future Directions  TBD(TBD) 
È޽Ġ01-19  13:10~13:30 Coffee Break  () 
±³À°½Ã°£ 01-19 Emerald Hall 13:30~13:55 Updates in management of HER2+ advanced disease  ¾ç¿¹¿ø(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 01-19 Emerald Hall 13:55~14:20 New options in metastatic Triple Negative Breast Cancer  ¹Ú°æÈ­(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 01-19 Emerald Hall 14:20~14:50 Special Lecture : Cardio-oncology  Jean-Bernard Durand(MD Anderson Cancer Center) 
Åä·Ð 01-19 Emerald Hall 14:30~14:40 Q & A  () 
È޽Ġ01-19  14:40~15:00 Coffee Break  () 
±³À°½Ã°£ 01-19 Emerald Hall 15:00~15:30 Evolving Standards of Care in HR+ Breast Cancer  ¼ÕÁÖÇõ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 01-19 Emerald Hall 15:30~16:00 20 years of targeting HER2 : Where are we now ?  ¹Ú¿¬Èñ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 01-19  16:00~16:10 Q & A  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of SABCS : 2019-01-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѺ´¸®ÇÐȸ ¼ÒÈ­±âÁúȯ Áø´Ü Ç¥ÁØÈ­ ¿öÅ©¼¥ : 2019-01-19
´ÙÀ½±Û ºÐ´ç¼­¿ï´ëÇб³º´¿ø Innovative Techiques and Complications (ôÃ߽űâ¼ú°ú ÇÕº´Áõ) : 2019-01-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21062 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(4ÀÏÂ÷) : 2024-07-04 0 120 2024-06-18
21061 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀçÅÃÀÇ·á ȯÀÚ Áø·áÀÇ ½ÇÁ¦ : 2024-07-04 0 71 2024-06-18
21060 ¿ï»ê ´ëÇÑ»êºÎÀΰúÀÇ»çȸ ¿ï»êÁöȸ ¿¬¼ö±³À°(¿ù°æÅë, µ¥³ë¼ö¹ä Áß´Ü ÈÄ ¹Ýµ¿°ñÀýÀÇ ¿¹¹æ) : 2024-07-04 0 98 2024-06-18
21059 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(3ÀÏÂ÷) : 2024-07-03 0 20 2024-06-18
21058 °æ±â 2024³â ÆòÅýÃÀÇ»çȸ ÇÏ°èÇмú´ëȸ : 2024-07-02 0 110 2024-06-18
21057 ¼­¿ï ¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(2ÀÏÂ÷) : 2024-07-02 0 83 2024-06-18
21056 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 64 2024-06-18
21055 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(1ÀÏÂ÷) : 2024-07-01 0 63 2024-06-18
21054 ÃæºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Understanding Current Community Mental Health and Emotional Disorders in ASD : 2024-07-01 0 93 2024-06-18
21053 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 59 2024-06-18
21052 °æ±â ´ëÇÑÁ¤ÇüÅëÁõÀÇÇÐȸ - Á¦2ȸ CHAMS °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 63 2024-06-18
21051 ¼­¿ï 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ ¼­¿ïÁöȸ Çϰ迬¼ö°­Á : 2024-06-30 0 78 2024-06-18
21050 ºÎ»ê 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2024-06-30 0 35 2024-06-18
21049 ¼­¿ï Á¦26Â÷ ´ëÇѾƵ¿º´¿øÇùȸ Ãá°èÇмú´ëȸ : 2024-06-30 0 26 2024-06-18
21048 Ãæ³² 2024 ÀÌ°úÇÐ ¿¬±¸¼¼¹Ì³ª : 2024-06-29 0 27 2024-06-18
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷